Article Text

This article has a correction. Please see:

Download PDFPDF

Microvascular Outcomes after Metabolic Surgery (MOMS) in patients with type 2 diabetes mellitus and class I obesity: rationale and design for a randomised controlled trial
  1. Ricardo Vitor Cohen1,
  2. Tiago Veiga Pereira2,
  3. Cristina Mamédio Aboud3,
  4. Pedro Paulo de Paris Caravatto1,
  5. Tarissa Beatrice Zanata Petry1,
  6. José Luis Lopes Correa1,
  7. Carlos Aurélio Schiavon4,
  8. Mariangela Correa3,
  9. Carlos Eduardo Pompílio1,
  10. Fernando Nogueira Quirino Pechy1,
  11. Carel le Roux5
  12. on behalf of MOMS Study Investigators
  1. 1The Center for Obesity and Diabetes, Oswaldo Cruz German Hospital, São Paulo, Brazil
  2. 2Health Technology Assessment Unit, Oswaldo Cruz German Hospital, São Paulo, Brazil
  3. 3Health Research Unit, Oswaldo Cruz German Hospital, São Paulo, Brazil
  4. 4Research Institute Hcor, Heart Hospital, São Paulo, Brazil
  5. 5Diabetes Complication Research Centre, UCD Conway Institute, School of Medicine and Medical Science, University College Dublin, Dublin, Ireland
  1. Correspondence to Dr Ricardo Vitor Cohen; ricardo.cohen{at}


Introduction There are several randomised controlled trials (RCTs) that have already shown that metabolic/bariatric surgery achieves short-term and long-term glycaemic control while there are no level 1A of evidence data regarding the effects of surgery on the microvascular complications of type 2 diabetes mellitus (T2DM).

Purpose The aim of this trial is to investigate the long-term efficacy and safety of the Roux-en-Y gastric bypass (RYGB) plus the best medical treatment (BMT) versus the BMT alone to improve microvascular outcomes in patients with T2DM with a body mass index (BMI) of 30–34.9 kg/m2.

Methods and analysis This study design includes a unicentric randomised unblinded controlled trial. 100 patients (BMI from 30 to 34.9 kg/m2) will be randomly allocated to receive either RYGB plus BMT or BMT alone. The primary outcome is the change in the urine albumin-to-creatinine ratio (uACR) captured as the proportion of patients who achieved nephropathy remission (uACR<30 mg/g of albumin/mg of creatinine) in an isolated urine sample over 12, 24 and 60 months.

Ethics and dissemination The study was approved by the local Institutional Review Board. This study represents the first RCT comparing RYGB plus BMT versus BMT alone for patients with T2DM with a BMI below 35 kg/m2.

Trial registration number NCT01821508; Pre-results.

  • gastric bypass
  • diabetes mellitus type 2
  • metabolic surgery

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors RVC, TVP, CMA, ClR and CMA conceived and designed the study and participated in logistical planning of the study, and were involved in the drafting of the article. TVP provided the statistical support for the sample size estimates and the design of the statistical analysis. TBZP and CEP were involved in the screening and randomisation process and are involved in the patient's follow-up. RVC, CAS, PPdPC, JLLC and FNQP performed all operations.

  • Funding The study is supported by a research grant from Johnson & Johnson Medical Brazil and Oswaldo Cruz German Hospital.

  • Competing interests None declared.

  • Ethics approval Local Institutional Review Board (IRB; Ethical Research Committee from Oswaldo Cruz German Hospital—#201681).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement The authors shall make data available to the scientific community with as few restrictions as feasible, ensuring anonymisation, while retaining exclusive use until the publication of major outputs.

Linked Articles

  • Miscellaneous
    Antonia Johnston